REVIEWS 89. et al.SirT2 i 61 o1o. 91. el.A.L z.A.Z.EOsta,A 119. 1.112 1158200 92 80.185185920101 95 0i at h L-6 pr 94. 122 a71 age.F.H. 16659-166 Proc 12.0 125 ed f D.ef t 126P 127 ol( 005 urg.A.B 280 H.& ma 101 drug targe 102. .C.E 65 105 105. sm 79. 106. 009 3 109. 200 V.M.Pr and in vivp 007 2-20201 of a 009 11. ed 112 20 c in the 4001-72010 d 285 87 oni,L,Bosco,D. end CLP 114 7,5 201 in INS-1E B-celis and 141 150. NATURE REVIEWSIDRUG DISCOVERY VOLUME 11 MAY 2012 399 2065. Covington, H. E. et al. Antidepressant actions of histone deacetylase inhibitors. J. Neurosci. 29, 11451–11460 (2009). 66. Loe-Mie, Y. et al. SMARCA2 and other genome-wide supported schizophrenia-associated genes: regulation by REST/NRSF, network organization and primate￾specific evolution. Hum. Mol. Genet. 19, 2841–2857 (2010). 67. Severinsen, J. E. et al. Evidence implicating BRD1 with brain development and susceptibility to both schizophrenia and bipolar affective disorder. Mol. Psychiatry 11, 1126–1138 (2006). 68. Lin, H. S. et al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen￾induced arthritis in rodents. Br. J. Pharmacol. 150, 862–872 (2007). 69. Grabiec, A. M., Korchynskyi, O., Tak, P. P. & Reedquist, K. A. Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann. Rheum. Dis. 71, 424–431 (2011). 70. Shakespear, M. R., Halili, M. A., Irvine, K. M., Fairlie, D. P. & Sweet, M. J. Histone deacetylases as regulators of inflammation and immunity. Trends Immunol. 32, 335–343 (2011). 71. Beier, U. H., Akimova, T., Liu, Y., Wang, L. & Hancock, W. W. Histone/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells. Curr. Opin. Immunol. 23, 670–678 (2011). 72. de Zoeten, E. F. et al. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3+ T-regulatory cells. Mol. Cell Biol. 31, 2066–2078 (2011). 73. Galli, M., Van Gool, F. & Leo, O. Sirtuins and inflammation: friends or foes? Biochem. Pharmacol. 81, 569–576 (2011). 74. Yoshizaki, T. et al. SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am. J. Physiol. Endocrinol. Metab. 298, e419–e428 (2010). 75. Ghizzoni, M., Haisma, H. J., Maarsingh, H. & Dekker, F. J. Histone acetyltransferases are crucial regulators in NF-κB mediated inflammation. Drug Discov. Today 16, 504–511 (2011). 76. Nicodeme, E. et al. Suppression of inflammation by a synthetic histone mimic. Nature 468, 1119–1123 (2010). 77. Chen, X., El Gazzar, M., Yoza, B. K. & McCall, C. E. The NF-κB factor RelB and histone H3 lysine methyltransferase G9a directly interact to generate epigenetic silencing in endotoxin tolerance. J. Biol. Chem. 284, 27857–27865 (2009). 78. van Essen, D., Zhu, Y. & Saccani, S. A feed-forward circuit controlling inducible NF-κB target gene activation by promoter histone demethylation. Mol. Cell 39, 750–760 (2010). 79. De Santa, F. et al. Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. EMBO J. 28, 3341–3352 (2009). 80. Ishii, M. et al. Epigenetic regulation of the alternatively activated macrophage phenotype. Blood 114, 3244–3254 (2009). 81. Ciavatta, D. J. et al. Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. J. Clin. Invest. 120, 3209–3219 (2010). 82. Hu, N. et al. Abnormal histone modification patterns in lupus CD4+ T cells. J. Rheumatol. 35, 804–810 (2008). 83. Zhong, L. & Mostoslavsky, R. Fine tuning our cellular factories: sirtuins in mitochondrial biology. Cell Metab. 13, 621–626 (2011). 84. Zillikens, M. C. et al. SIRT1 genetic variation is related to BMI and risk of obesity. Diabetes 58, 2828–2834 (2009). 85. Cardellini, M. et al. TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1. Diabetes 58, 2396–2401 (2009). 86. Orimo, M. et al. Protective role of SIRT1 in diabetic vascular dysfunction. Arterioscler. Thromb. Vasc. Biol. 29, 889–894 (2009). 87. Vetterli, L., Brun, T., Giovannoni, L., Bosco, D. & Maechler, P. Resveratrol potentiates glucose￾stimulated insulin secretion in INS-1E β-cells and human islets through a SIRT1-dependent mechanism. J. Biol. Chem. 286, 6049–6060 (2011). 88. Ramadori, G. et al. Central administration of resveratrol improves diet-induced diabetes. Endocrinology 150, 5326–5333 (2009). 89. Fischer-Posovszky, P. et al. Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. Am. J. Clin. Nutr. 92, 5–15 (2010). 90. Brasacchio, D. et al. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes 58, 1229–1236 (2009). 91. Siebel, A. L., Fernandez, A. Z. & El-Osta, A. Glycemic memory associated epigenetic changes. Biochem. Pharmacol. 80, 1853–1859 (2010). 92. Meissner, A. Epigenetic modifications in pluripotent and differentiated cells. Nature Biotech. 28, 1079–1088 (2010). 93. Borowiak, M. et al. Small molecules efficiently direct endodermal differentiation of mouse and human embryonic stem cells. Cell Stem Cell 4, 348–358 (2009). 94. Hsieh, J., Nakashima, K., Kuwabara, T., Mejia, E. & Gage, F. H. Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells. Proc. Natl Acad. Sci. USA 101, 16659–16664 (2004). 95. Hao, Y. et al. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J. Neurosci. 24, 6590–6599 (2004). 96. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663–676 (2006). 97. Huangfu, D. et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nature Biotech. 26, 1269–1275 (2008). 98. Shi, Y. et al. A combined chemical and genetic approach for the generation of induced pluripotent stem cells. Cell Stem Cell 2, 525–528 (2008). 99. de Ruijter, A. J., van Gennip, A. H., Caron, H. N., Kemp, S. & van Kuilenburg, A. B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370, 737–749 (2003). 100. Finnin, M. S. et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401, 188–193 (1999). 101. Sauve, A. A. Sirtuin chemical mechanisms. Biochim. Biophys. Acta 1804, 1591–1603 (2010). 102. Sauve, A. A., Wolberger, C., Schramm, V. L. & Boeke, J. D. The biochemistry of sirtuins. Annu. Rev. Biochem. 75, 435–465 (2006). 103. Choudhary, C. et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834–840 (2009). 104. Kovacs, J. J. et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 18, 601–607 (2005). 105. Hubbert, C. et al. HDAC6 is a microtubule-associated deacetylase. Nature 417, 455–458 (2002). 106. Prince, H. M., Bishton, M. J. & Harrison, S. J. Clinical studies of histone deacetylase inhibitors. Clin. Cancer Res. 15, 3958–3969 (2009). 107. Grant, S., Easley, C. & Kirkpatrick, P. Vorinostat. Nature Rev. Drug Discov. 6, 21–22 (2007). 108. Marks, P. A. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin. Investig. Drugs 19, 1049–1066 (2010). 109. Butler, L. M. et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60, 5165–5170 (2000). This was the first evidence that an HDAC inhibitor has anticancer activity in an animal model. 110. Schapira, M. Structural biology of human metal￾dependent histone deacetylases. Handb. Exp. Pharmacol. 206, 225–240 (2011). 111. Bradner, J. E. et al. Chemical phylogenetics of histone deacetylases. Nature Chem. Biol. 6, 238–243 (2010). 112. Lahm, A. et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc. Natl Acad. Sci. USA 104, 17335–17340 (2007). 113. Schuetz, A. et al. Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J. Biol. Chem. 283, 11355–11363 (2008). 114. Mihaylova, M. M. et al. Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis. Cell 145, 607–621 (2011). 115. Bantscheff, M. et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nature Biotech. 29, 255–265 (2011). 116. Vaquero, A. et al. SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes Dev. 20, 1256–1261 (2006). 117. Vaquero, A. et al. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol. Cell 16, 93–105 (2004). 118. Vempati, R. K. et al. p300-mediated acetylation of histone H3 lysine 56 functions in DNA damage response in mammals. J. Biol. Chem. 285, 28553–28564 (2010). 119. Michishita, E. et al. SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature 452, 492–496 (2008). 120. Du, J. et al. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science 334, 806–809 (2011). 121. Liu, B. et al. Identification and characterization of propionylation at histone H3 lysine 23 in mammalian cells. J. Biol. Chem. 284, 32288–32295 (2009). 122. Vaziri, H. et al. hSIR2(SIRT1) functions as an NAD￾dependent p53 deacetylase. Cell 107, 149–159 (2001). 123. Haigis, M. C. & Sinclair, D. A. Mammalian sirtuins: biological insights and disease relevance. Annu. Rev. Pathol. 5, 253–295 (2010). 124. Milne, J. C. et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450, 712–716 (2007). 125. Stunkel, W. & Campbell, R. M. Sirtuin 1 (SIRT1): the misunderstood HDAC. J. Biomol. Screen. 16, 1153–1169 (2011). 126. Pacholec, M. et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem. 285, 8340–8351 (2010). 127. Solomon, J. M. et al. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol. Cell Biol. 26, 28–38 (2006). 128. Liu, X. et al. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature 451, 846–850 (2008). 129. Piaz, F. D. et al. Chemical biology of histone acetyltransferase natural compounds modulators. Mol. Divers. 15, 401–416 (2011). 130. Dekker, F. J. & Haisma, H. J. Histone acetyl transferases as emerging drug targets. Drug Discov. Today 14, 942–948 (2009). 131. Wisastra, R. et al. Isothiazolones; thiol-reactive inhibitors of cysteine protease cathepsin B and histone acetyltransferase PCAF. Org. Biomol. Chem. 9, 1817–1822 (2011). 132. Lau, O. D. et al. HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol. Cell 5, 589–595 (2000). 133. Bowers, E. M. et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem. Biol. 17, 471–482 (2010). 134. Santer, F. R. et al. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Mol. Cancer Ther. 10, 1644–1655 (2011). 135. Spannhoff, A., Hauser, A. T., Heinke, R., Sippl, W. & Jung, M. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors. ChemMedChem 4, 1568–1582 (2009). 136. Copeland, R. A., Solomon, M. E. & Richon, V. M. Protein methyltransferases as a target class for drug discovery. Nature Rev. Drug Discov. 8, 724–732 (2009). 137. Kubicek, S. et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol. Cell 25, 473–481 (2007). This was the first example of selective, substrate-competitive inhibition of a histone methyltransferase. 138. Chang, Y. et al. Adding a lysine mimic in the design of potent inhibitors of histone lysine methyltransferases. J. Mol. Biol. 400, 1–7 (2010). 139. Liu, F. et al. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy￾quinazolines. J. Med. Chem. 53, 5844–5857 (2010). 140. Vedadi, M. et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nature Chem. Biol. 7, 566–574 (2011). 141. Chang, Y. et al. Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nature Struct. Mol. Biol. 16, 312–317 (2009). 142. Ferguson, A. D. et al. Structural basis of substrate methylation and inhibition of SMYD2. Structure 19, 1262–1273 (2011). REVIEWS NATURE REVIEWS | DRUG DISCOVERY VOLUME 11 | MAY 2012 | 399 © 2012 Macmillan Publishers Limited. All rights reserved